Remove 2017 Remove Immunization Remove Vaccines
article thumbnail

Key vaccine adjuvant biosynthesised

European Pharmaceutical Review

A paper, published in Nature Chemical Biology has reported the first ‘free-from ‘tree’ production of a key vaccine ingredient sourced from the soapbark tree. Bioengineering vaccine adjuvants The paper explained: “QS-21 is a potent vaccine adjuvant currently sourced by extraction from the Chilean soapbark tree.

article thumbnail

Vaxxas announces CEPI partnership to advance needle-free mRNA vaccine patches

pharmaphorum

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology with preclinical testing of an mRNA vaccine patch. The agreement, worth $4.3

Vaccines 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Microparticles could form self-boosting vaccines

European Pharmaceutical Review

According to the authors, the technology could enable the creation of “self-boosting” vaccines that only need to be administered once, which could be particularly beneficial for childhood vaccinations in regions with limited access to medical care. The lid- and cup-shaped particles are formed using an array of silicon moulds.

Vaccines 105
article thumbnail

Towards ‘smart’ vaccine development and manufacturing

European Pharmaceutical Review

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

article thumbnail

Recombinant shingles vaccine could protect against dementia onset, study suggests

Hospital Pharmacy Europe

The shingles vaccine that has been used in the NHS since last year is associated with a reduced risk of dementia, researchers have reported. A study of more than 200,000 adults before and after the US switched from Zostavax to the Shingrix vaccine found at least a 17% reduction in dementia diagnoses.

article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot. GlaxoSmithKline has agreed a $3.3

article thumbnail

Three-dose vaccine prevents HIV patients getting hepatitis B

European Pharmaceutical Review

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. At week 28, the study assessed the vaccine’s safety and levels of anti-HBV surface antibodies (HBsAbs).